Brickell Biotech to Report Second Quarter 2020 Financial Results and Provide a Corporate Update on August 12, 2020

Rhea-AI Summary

Brickell Biotech, Inc. (Nasdaq: BBI), a clinical-stage pharmaceutical company, will report its Q2 2020 financial results on August 12, 2020, after market close. Management will host a conference call at 4:30 PM ET to discuss financial results and corporate highlights. Brickell focuses on developing innovative therapeutics for skin diseases, including hyperhidrosis. The management team has extensive experience in product development, having worked on several successful products in the pharmaceutical and biotech industries.

BOULDER, Colo., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that it will report its financial results for the second quarter ended June 30, 2020, after the market close on Wednesday, August 12, 2020. Brickell’s management will host a conference call and webcast at 4:30pm ET to discuss the financial results and recent corporate highlights.

To access the call, please dial 877-705-6003 in the U.S. or 201-493-6725 outside the U.S. and provide the conference ID number: 13706625. To access the live webcast, please go to the investors section of Brickell’s website at https://ir.brickellbio.com/events-presentations. Following the live webcast, an archived version of the call will be available on the website.

About Brickell Bio
Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases. Brickell’s pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions. Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis^®, Taltz^®, Gemzar^®, Prozac^®, Cymbalta^® and Juvederm^®. Brickell’s strategy is to leverage this experience to in-license, acquire, develop, and commercialize innovative products that Brickell believes can be successful in the currently underserved dermatology global marketplace. For more information, visit http://www.brickellbio.com.

Brickell Investor Contact:
IR@brickellbio.com 

FAQ

When will Brickell Biotech report its Q2 2020 financial results?

Brickell Biotech will report its Q2 2020 financial results on August 12, 2020, after market close.

What time is Brickell Biotech's conference call?

The conference call to discuss Q2 2020 financial results will take place at 4:30 PM ET on August 12, 2020.

How can I access the Brickell Biotech conference call?

To access the call, dial 877-705-6003 in the U.S. or 201-493-6725 outside the U.S., using conference ID 13706625. The call can also be accessed via a live webcast on their investor website.

What therapeutic areas does Brickell Biotech focus on?

Brickell Biotech focuses on developing therapeutics for debilitating skin diseases, including hyperhidrosis.

What is the focus of Brickell's management team?

Brickell’s management team has extensive experience in product development and global commercialization in the pharmaceutical sector.